1,4-Benzodiazepone-2,5-Diones And Related Compounds With Therapeutic Properties

A method of treating a fibrosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of a formula selected from the group consisting of:

• substituted and unsubstituted, including both R and S enantiomeric forms and racemic mixtures;
• wherein R2 is selected from the group consisting of —H, alkyl, and substituted alkyl;
• wherein R3 is selected from the group consisting of —H, alkyl, substituted alkyl, OH, aryl, substituted aryl, cycloaliphatic, substituted cycloaliphatic, heterocycle, substituted heterocycle, a chemical moiety comprising at least one ester, a chemical moiety comprising at least one ether, a linear or branched, saturated or unsaturated, substituted or non-substituted, aliphatic chain having at least 2 carbons, a chemical moiety comprising a sulfur, a chemical moiety comprising nitrogen, and —OR,
• wherein R is selected from the group consisting of aryl, substituted aryl, a cycloaliphatic, a substituted cycloaliphatic, a heterocycle;
• a substituted heterocycle, a linear or branched, saturated or unsaturated, substituted or non-substituted, aliphatic chain having at least 2 carbons, a chemical moiety comprising at least one ester subgroup, a chemical moiety comprising at least one ether subgroup, a chemical moiety comprising sulfur, and a chemical moiety comprising nitrogen;
• wherein R4 is selected from the group consisting of C, N, S, and O;
• wherein R5 is selected from the group consisting of —H, alkyl, substituted alkyl, mono-substituted aryl, di-substituted aryl, and tri-substituted aryl;
• wherein R6 is selected from the group consisting of C, N, S and O;
• wherein R7, R8, R9, and R10 are independently selected from the group consisting of being absent, —H, halogen, CF3,
• —OH, fluoroalkyl, sulfonamide, -sulfone, —OCH3, —CH3, —SO2R28, —SO2N(R7′)2, —OR7′, —N(R7′)2, —CON(R7′)2, —NHCOR7′, —NHSO2R7′, alkyl, mono-substituted alkyl, di-substituted alkyl, tri-substituted alkyl;
• wherein R7′ is selected from the group consisting of halogen, H, alkyl, mono-substituted alkyl, di-substituted alkyl, tri-substituted alkyl, aryl, mono-substituted aryl, di-substituted aryl, tri-substituted aryl, cycloalipathic, mono-substituted cycloalipathic, di-substituted cycloalipathic, and tri-substituted cycloalipathic;
• wherein R11, R12, R13, and R14, are independently selected from the group consisting of —H, alkyl, fluoroalkyl,
• and substituted and unsubstituted, and derivatives thereof;
• wherein R15, R16, R17, and R18 are independently selected from the group consisting of C, N, O, and S;
• wherein R19 forms a ketone with the carbon to which it is attached;
• wherein R20 forms a ketone with the carbon to which it is attached;
• wherein R21, R22, R23, and R24 are independently selected from the group consisting of being absent, H, halogen, CF3,
• —OH, fluoroalkyl, sulfonamide, sulfone, —OCH3, —CH3, —SO2R7′, —SO2N(R7′)2, —OR7′, —N(R7′)2, —CON(R7′)2, —NHCOR7′, —NHSO2R7′, alkyl, mono- substituted alkyl, di-substituted alkyl, tri-substituted alkyl, wherein no more than two of R21, R22, R23 and R24 can be hydrogen;
• and
• wherein R25, R26, R27, and R28, are independently selected from the group consisting of hydrogen, alkyl, fluoroalkyl,
• and substituted and unsubstituted, and derivatives thereof, wherein no more than three of R25, R26, R27 and R28 can be hydrogen.